In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:

• The epidemiological challenge of rare diseases and representing the topic at the White House


• Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?


• The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca


• Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions

Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity. 

Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.

Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.